In addition, removing galectin-3 from cell surface CD45 enhanced the phosphorylation activity, thereby increasing the sensitivity of DLBCL cells to chemotherapeutic drug-induced death. This evidence concerns the gene PTPRC and diffuse large B-cell lymphoma.